Your browser is no longer supported. Please, upgrade your browser.
Settings
MIST [NASD]
Milestone Pharmaceuticals Inc.
Index- P/E- EPS (ttm)-0.92 Insider Own9.29% Shs Outstand42.18M Perf Week-4.74%
Market Cap188.14M Forward P/E- EPS next Y-1.64 Insider Trans0.00% Shs Float27.10M Perf Month6.54%
Income-34.60M PEG- EPS next Q-0.43 Inst Own74.30% Short Float0.64% Perf Quarter-4.13%
Sales15.00M P/S12.54 EPS this Y51.30% Inst Trans-0.82% Short Ratio5.34 Perf Half Y-0.33%
Book/sh3.02 P/B2.00 EPS next Y-46.40% ROA-24.40% Target Price13.60 Perf Year-9.32%
Cash/sh4.05 P/C1.49 EPS next 5Y- ROE-25.60% 52W Range5.09 - 9.03 Perf YTD-10.00%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-33.25% Beta-
Dividend %- Quick Ratio22.70 Sales past 5Y- Gross Margin- 52W Low18.47% ATR0.29
Employees28 Current Ratio22.70 Sales Q/Q- Oper. Margin- RSI (14)51.76 Volatility5.43% 4.92%
OptionableYes Debt/Eq0.00 EPS Q/Q16.20% Profit Margin- Rel Volume0.37 Prev Close6.02
ShortableYes LT Debt/Eq0.00 EarningsNov 12 BMO Payout- Avg Volume32.21K Price6.03
Recom1.80 SMA201.55% SMA504.08% SMA2001.39% Volume11,965 Change0.17%
Mar-05-21Initiated H.C. Wainwright Buy $20
Jul-29-20Upgrade Oppenheimer Perform → Outperform $18
Jul-24-20Upgrade Jefferies Hold → Buy
Mar-25-20Downgrade Jefferies Buy → Hold $28 → $3
Mar-24-20Downgrade Piper Sandler Overweight → Neutral $26.50 → $3
Mar-24-20Downgrade Oppenheimer Outperform → Perform
Jun-04-19Initiated Oppenheimer Outperform $32
Jun-03-19Initiated Piper Jaffray Overweight $26.50
Jun-03-19Initiated Jefferies Buy $28
Jun-03-19Initiated Cowen Outperform $32
Nov-15-21 07:00AM  
Nov-12-21 07:20AM  
Nov-11-21 07:00AM  
Oct-15-21 09:31AM  
Sep-22-21 07:00AM  
07:00AM  
Sep-07-21 07:00AM  
07:00AM  
Aug-16-21 10:58AM  
Aug-11-21 04:18PM  
04:18PM  
Aug-03-21 09:01AM  
May-26-21 07:00AM  
07:00AM  
May-17-21 01:22PM  
07:02AM  
07:02AM  
07:01AM  
07:01AM  
07:00AM  
07:00AM  
May-04-21 09:04AM  
May-03-21 06:47AM  
Apr-02-21 11:59AM  
Mar-29-21 05:32PM  
05:32PM  
05:30PM  
05:30PM  
Mar-05-21 10:29AM  
Feb-25-21 07:00AM  
Feb-01-21 04:35AM  
Jan-29-21 05:13PM  
Dec-02-20 10:11PM  
06:08AM  
Nov-23-20 04:44PM  
07:00AM  
07:00AM  
Nov-18-20 07:00AM  
07:00AM  
Nov-13-20 07:00AM  
07:00AM  
Nov-11-20 07:00AM  
Oct-23-20 07:00AM  
07:00AM  
Oct-22-20 04:01PM  
04:01PM  
Sep-22-20 07:00AM  
Sep-08-20 07:00AM  
07:00AM  
Aug-12-20 07:00AM  
Aug-10-20 07:47AM  
Aug-06-20 07:00AM  
Aug-04-20 09:04AM  
Jul-31-20 12:34PM  
Jul-24-20 06:17PM  
02:19PM  
Jul-23-20 07:00AM  
07:00AM  
07:00AM  
Jun-12-20 06:39AM  
Jun-10-20 08:37AM  
Jun-05-20 02:46PM  
May-27-20 07:00AM  
May-20-20 10:00AM  
08:33AM  
May-19-20 07:22AM  
May-14-20 07:15AM  
07:15AM  
Apr-20-20 10:38AM  
Apr-02-20 01:23PM  
Apr-01-20 10:15AM  
Mar-25-20 10:34AM  
Mar-24-20 08:20AM  
Mar-23-20 11:08PM  
04:05PM  
Mar-06-20 07:00AM  
07:00AM  
Feb-04-20 09:22AM  
Jan-15-20 07:00AM  
Dec-20-19 06:20PM  
Nov-27-19 07:00AM  
Nov-14-19 07:00AM  
07:00AM  
Nov-13-19 07:00AM  
Oct-03-19 07:00AM  
Sep-10-19 07:00AM  
07:00AM  
Aug-13-19 07:00AM  
07:00AM  
Aug-08-19 11:39AM  
Aug-06-19 07:00AM  
07:00AM  
May-30-19 07:00AM  
May-21-19 04:05PM  
04:05PM  
May-14-19 06:40PM  
May-13-19 04:05PM  
May-08-19 11:02PM  
May-06-19 09:47AM  
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. It is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, as well as in the Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate, and other cardiovascular indications. Milestone Pharmaceuticals Inc. has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil in patients with paroxysmal supraventricular tachycardia and additional cardiovascular conditions in Greater China. The company was incorporated in 2003 and is headquartered in Montreal, Canada.